---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-329000"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2021-11-15T23:59:59+00:00"
generated_at: "2026-06-28T08:27:50.993582+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# UroGen Q3 Jelmyto rev $11.4M; ends Allergan pact; shifts UGN-102 trial to single-arm Phase 3

## Summary
- Q3 2021 net product revenue $11.4M; net loss $30.2M ($1.35/share) vs $28.8M loss ($1.31) in Q3 2020.
- Full-year 2021 revenue guidance $47-51M; operating expense guidance reduced to $137-142M from $155-165M.
- Ceased enrollment in ATLAS Phase 3 for UGN-102; new single-arm Phase 3 trial planned for early 2022; NDA submission expected 2024.
- Mutually terminated license agreement with Allergan effective November 11, 2021.
- Cash and equivalents $110.3M as of Sep 30; Jelmyto site activations up 73% since August 1.

## SEC filing metadata
- accession: 0001193125-21-329000
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2021-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.02, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312521329000/0001193125-21-329000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312521329000/d243248d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-329000
- JSON: https://secwatch.observer/filing/0001193125-21-329000.json
- Plain text: https://secwatch.observer/filing/0001193125-21-329000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.